Who are Hyaluronic Acid and hydroxypropylmethylcellulose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Meticel Ofteno®, Retaine™, TJO-018 (HA 0.15%), Lipid-Based Artificial Tear, preservative-free 0.15% HA, Systane Ultra Preservative Free.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hyaluronic-acid-and-hydroxypropylmethylcellulose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Hyaluronic Acid and hydroxypropylmethylcellulose — Competitive Intelligence Brief

Hyaluronic Acid and hydroxypropylmethylcellulose (Hyaluronic Acid and hydroxypropylmethylcellulose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Artificial tear / ocular lubricant. Area: Ophthalmology.

marketed Artificial tear / ocular lubricant Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Hyaluronic Acid and hydroxypropylmethylcellulose (Hyaluronic Acid and hydroxypropylmethylcellulose) — University of Sao Paulo. Hyaluronic acid and hydroxypropylmethylcellulose form a viscoelastic lubricating and protective coating on the ocular surface.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Hyaluronic Acid and hydroxypropylmethylcellulose TARGET	Hyaluronic Acid and hydroxypropylmethylcellulose	University of Sao Paulo	marketed	Artificial tear / ocular lubricant
Meticel Ofteno®	Meticel Ofteno®	Laboratorios Sophia S.A de C.V.	marketed	Artificial tear / Ocular lubricant
Retaine™	Retaine™	Ocusoft, Inc.	marketed	Artificial tear / ocular lubricant
TJO-018 (HA 0.15%)	TJO-018 (HA 0.15%)	Taejoon Pharmaceutical Co., Ltd.	marketed	Artificial tear / Ocular lubricant	Ocular surface (non-receptor mediated)
Lipid-Based Artificial Tear	Lipid-Based Artificial Tear	University of Seville	marketed	Artificial tear / Ocular lubricant
preservative-free 0.15% HA	preservative-free 0.15% HA	Chang Gung Memorial Hospital	marketed	Artificial tear / ocular lubricant
Systane Ultra Preservative Free	Systane Ultra Preservative Free	Laboratorios Sophia S.A de C.V.	marketed	Artificial tear / Ocular lubricant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Artificial tear / ocular lubricant class)

Allergan · 2 drugs in this class
Chang Gung Memorial Hospital · 1 drug in this class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Nguyen Viet Giap · 1 drug in this class
ORA, Inc. · 1 drug in this class
Ocusoft, Inc. · 1 drug in this class
The Mentholatum Company · 1 drug in this class
Tianjin Eye Hospital · 1 drug in this class
University of Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hyaluronic Acid and hydroxypropylmethylcellulose — Competitive Intelligence Brief. https://druglandscape.com/ci/hyaluronic-acid-and-hydroxypropylmethylcellulose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab